NCT00089674View on ClinicalTrials.gov

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

1,468

Participants

Timeline

Start Date

August 1, 2004

Primary Completion Date

May 16, 2008

Study Completion Date

May 11, 2010

Conditions

Prostate Cancer

Interventions

DRUG

AMG 162

60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30

DRUG

Placebo

60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT00089674 - AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter